Cooperation contract with university hospital Erlangen extended for 2021
The ImmunoLogik and the university hospital Erlangen decided to continue their successful cooperation and agreed on an extension of the cooperation contract until September 2021.
Without the cooperation between ImmunoLogik and the university hospital Erlangen for the development of the innovative lead candidate IML-106 for the efficient and essential treatment of HIV patients who have exploited all available means of the modern therapy and would die due to the unavoidable outbreak of AIDS, the identification of IML-206 against SARS-CoV-2 could have never been made. Only with the right scientific partners, infrastructure with laboratories of the biosafety level 2 and 3 and access to virus isolates ImmunoLogik was able to identify and test the promising approach of IML-206 so quickly.
Therewith, the cooperation was and is still an important building block for the development of the innovative lead candidate IML-206 for the treatment of diseases caused by SARS-CoV-2 and other future coronaviruses.
It is a cooperation which takes into account the interests of all parties and therewith is advantageous for both parties. For the ImmunoLogik it means to maintain the access to laboratories of the biosafety level 2 and 3, special equipment and especially highly qualified scientist in the narrower and wider network, e.g. Bernhard Nocht Institute for Tropical Medicine and the university hospital Tubingen. Particularly, the exchange among scientists and domain experts is of vital importance for the mutual success and further development of IML-206.
Therewith the ImmunoLogik meets the expectations of its investors, to conduct the upcoming work for the generation of data packages about the in vivo efficacy and toxicity, as well the explanation of the mode of action of IML-206.
Christian Setz summarizes it this way: ”We are very happy that we could extent the cooperation contract with the university hospital Erlangen successfully and therewith maintain the access to laboratories of the biosafety level 2 and 3 and the network of experienced virologists. Without this extension the upcoming development work on IML-206 and IML-106 would be possible only with a considerable amount of money.“
Image source: PublicDomainPictures – pixabay.com